Hadasit Bio (HDST) - Net Assets

Latest as of June 2023: ILA10.94 Million ILA ≈ $29.34K USD

Based on the latest financial reports, Hadasit Bio (HDST) has net assets worth ILA10.94 Million ILA (≈ $29.34K USD) as of June 2023. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA14.67 Million ≈ $39.33K USD) and total liabilities (ILA3.73 Million ≈ $9.99K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hadasit Bio liquidity resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	ILA10.94 Million
% of Total Assets	74.61%
Annual Growth Rate	5.03%
5-Year Change	2.26%
10-Year Change	40.95%
Growth Volatility	162.41

Hadasit Bio - Net Assets Trend (2008–2022)

This chart illustrates how Hadasit Bio's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Hadasit Bio for the complete picture of this company's asset base.

Annual Net Assets for Hadasit Bio (2008–2022)

The table below shows the annual net assets of Hadasit Bio from 2008 to 2022. For live valuation and market cap data, see HDST stock market capitalisation.

Year	Net Assets	Change
2022-12-31	ILA35.08 Million ≈ $94.04K	-46.60%
2021-12-31	ILA65.69 Million ≈ $176.12K	+77.03%
2020-12-31	ILA37.11 Million ≈ $99.49K	+574.57%
2019-12-31	ILA5.50 Million ≈ $14.75K	-83.96%
2018-12-31	ILA34.30 Million ≈ $91.96K	-43.57%
2017-12-31	ILA60.79 Million ≈ $162.97K	-1.35%
2016-12-31	ILA61.62 Million ≈ $165.20K	+2.19%
2015-12-31	ILA60.30 Million ≈ $161.66K	+172.71%
2014-12-31	ILA22.11 Million ≈ $59.28K	-11.15%
2013-12-31	ILA24.89 Million ≈ $66.72K	-30.60%
2012-12-31	ILA35.86 Million ≈ $96.14K	+0.70%
2011-12-31	ILA35.61 Million ≈ $95.47K	-32.88%
2010-12-31	ILA53.06 Million ≈ $142.25K	+8.21%
2009-12-31	ILA49.03 Million ≈ $131.46K	+178.01%
2008-12-31	ILA17.64 Million ≈ $47.29K	--

Equity Component Analysis

This analysis shows how different components contribute to Hadasit Bio's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 10570300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2022)

Component	Amount	Percentage
Other Components	ILA140.78 Million	401.34%
Total Equity	ILA35.08 Million	100.00%

Hadasit Bio Competitors by Market Cap

The table below lists competitors of Hadasit Bio ranked by their market capitalization.

Company	Market Cap
UIL Ltd LSE:UTL	$2.16 Million
PBS Finanse SA WAR:PBF	$2.16 Million
Jadestone Energy Inc LSE:JSE	$2.16 Million
WINDFALL GEOTEK F:L7C2	$2.16 Million
Sungmoon Electronics Co Ltd KO:014915	$2.16 Million
Stinger Resources Inc V:STNG	$2.15 Million
Key Alliance Group Bhd KLSE:0036	$2.15 Million
Lucapa Diamond Co Ltd F:NHY	$2.15 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hadasit Bio's equity between the two most recent reporting periods.

Equity Growth Insights

From 2021 to 2022, total equity changed from 65,692,000 to 35,078,000, a change of -30,614,000 (-46.6%).
Net loss of 31,211,000 reduced equity.
Other factors increased equity by 597,000.

Equity Change Factors (2021 to 2022)

Factor	Impact	Contribution
Net Income	ILA-31.21 Million	-88.98%
Other Changes	ILA597.00K	+1.7%
Total Change	ILA-	-46.60%

Book Value vs Market Value Analysis

This analysis compares Hadasit Bio's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 22.92x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 23.23x to 22.92x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	ILA3.12	ILA72.50	x
2018-12-31	ILA3.10	ILA72.50	x
2019-12-31	ILA0.49	ILA72.50	x
2020-12-31	ILA3.34	ILA72.50	x
2021-12-31	ILA5.92	ILA72.50	x
2022-12-31	ILA3.16	ILA72.50	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hadasit Bio utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -88.98%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 1.11x
Recent ROE (-88.98%) is below the historical average (-59.91%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	-84.74%	0.00%	0.00x	1.94x	ILA-16.98 Million
2014	-42.34%	0.00%	0.00x	2.16x	ILA-7.86 Million
2015	-128.11%	0.00%	0.00x	5.28x	ILA-17.94 Million
2016	-9.92%	0.00%	0.00x	4.22x	ILA-3.28 Million
2017	38.25%	3659.44%	0.01x	1.99x	ILA9.73 Million
2018	-0.92%	-126.40%	0.01x	1.03x	ILA-3.74 Million
2019	-409.76%	-96934.78%	0.00x	1.73x	ILA-22.84 Million
2020	84.26%	0.00%	0.00x	1.12x	ILA27.50 Million
2021	43.18%	0.00%	0.00x	1.01x	ILA21.79 Million
2022	-88.98%	0.00%	0.00x	1.11x	ILA-34.72 Million

Industry Comparison

This section compares Hadasit Bio's net assets metrics with peer companies in the Biotechnology & Medical Research industry.

Industry Context

Industry: Biotechnology & Medical Research
Average net assets among peers: $20,812,000
Average return on equity (ROE) among peers: -30.46%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Hadasit Bio (HDST)	ILA10.94 Million	-84.74%	0.34x	$2.16 Million
Purple Biotech Ltd (KTOV)	$3.47 Million	0.00%	1.20x	$461.41K
Pluristem (PSTI)	$38.16 Million	-60.92%	0.20x	$65.47 Million

About Hadasit Bio

TA:HDST Israel Biotechnology & Medical Research

Market Cap

$2.16 Million

ILA803.92 Million ILA

Market Cap Rank

#29806 Global

#438 in Israel

Share Price

ILA72.50

Change (1 day)

+0.00%

52-Week Range

ILA28.10 - ILA83.00

All Time High

ILA2847.77